Frontlight ResearchEarly access
CompletedPhase 2
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Birmingham, Boston, Burlington, Columbus, Corvallis, Dallas, Evanston, Iowa City, Johns Creek, Murray, Pittsburgh, Rochester, San Francisco, Springfield, Stanford, The Bronx, and Winston-Salem, United StatesSee the 18 sitesAlso in 17 other countries, 80 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 316 people enrolled
- Started
- 18 Jan 2024
- Ended
- 14 May 2026
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TIN816 70 mg lyophilisate powder
- Placebo
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- Signed informed consent must be obtained in accordance with local regulations
- ≥ 18 to ≤ 85 years of age
- Admitted to ICU or intermediate care unit/ high dependency care unit (HDU)
- Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:; Suspected or confirmed infection AND; Acute increase of SOFA score of 2 or more (excluding renal component). The baseline SOFA score should be assumed to be zero unless the participant is known to have pre-existing (acute or chronic) organ dysfunction before the onset of infection
- Diagnosis of AKI Stage 1 or greater per the following criterion at randomization:; An absolute increase in serum or plasma creatinine by ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference serum creatinine
- For participants with hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI diagnosis should be used as the reference serum creatinine
- For participants presenting from community, the reference serum creatinine should be estimated using the following order of preference:; The most recent value within 3 months of the hospital admission. If not available:; The most recent value between 3 and 12 months prior to hospital admission. If not available:; At hospital admission
Who cannot take part
- Receiving RRT or a decision has been made to initiate RRT within 24 hours after randomization
- Sepsis diagnosis according to sepsis inclusion criteria for a period longer than 72 hours prior to ICU admission
- Inability to administer study drug within 24 hours of diagnosis of AKI according to AKI inclusion criteria
- Presence of AKI, in the Investigator's opinion, as suggested by clinical manifestation, e.g., prolonged oliguria or severe renal dysfunction on admission without a history of CKD, for a period longer than 24 hours prior to study drug administration
- Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization
- AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides, etc.) or renal perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery stenosis), urinary obstruction
- Immunosuppressed patients; History of immunodeficiency diseases; Receiving immunosuppressant treatment or on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with corticosteroids (as per the Surviving Sepsis Guidelines) can be included
- Patients with known or presumed latent or active TB based on clinical history or imaging e.g. patients on TB preventive therapy or close/household contacts of pulmonary TB patients
- Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable)
- Use of other investigational drugs within 5 half-lives of enrollment, within 30 days (e.g., small molecules) or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations
- Not expected to survive for 30 days due to medical conditions other than SA-AKI
- Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN)
- Known active hepatitis B or C infection (clinical diagnosis or positive infection serology), or advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C)
- Acute pancreatitis with no established source of infection
- Sepsis attributed to confirmed COVID-19
- History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes
- Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement
- History of CKD with a documented estimated GFR <30 mL/min prior to admission to hospital
- eGFR <45mL/min at admission without any other reference serum eGFR within last 12-months
- Patients who are thrombocytopenic at screening (platelet count <50,000 per microliter) who have active/uncontrolled bleeding or who present current or past conditions indicating high risk for bleeding in the opinion of the investigator (e.g. coagulopathies, previous history of major non-traumatic bleeding etc.)
- Not expected to survive for 24 hours
- Weight is less than 40 kg or more than 125 kg
- Limitations to the use of mechanical ventilation, RRT or vasopressors/inotropes (N.B. limitations on Cardiopulmonary resuscitation (CPR)e.g., do-not-resuscitate orders are not an exclusion criterion unless associated with likely poor outcome in next 24 hours)
- AKI diagnosis according to AKI inclusion criteria over 48 hours after admission to ICU
- Patients who are post-nephrectomy
- Patients with permanent incapacitation
- Burns requiring ICU treatment
- Women with a positive pregnancy test, pregnancy or breast feeding
- Women of childbearing potential, unless they are using highly effective methods of contraception for the entire duration of the trial
Where in United States
Also in 17 other countries, 80 sites
- University of AlabamaBirmingham, United States
- Beth Israel Deaconess Med CenterBoston, United States
- Massachusetts General HospitalBoston, United States
- Lahey Hospital and Medical CenterBurlington, United States
- Ohio State University Medical CenterColumbus, United States
- Good Samaritan HospitalCorvallis, United States
- Baylor Scott and WhiteDallas, United States
- Northwestern Memorial HospitalEvanston, United States
- Univ Of Iowa Hospitals And ClinicsIowa City, United States
- Emory Johns Creek HospitalJohns Creek, United States
- Utah Intermountain Medical CenterMurray, United States
- U Of Pittsburgh Med CtrPittsburgh, United States
- Mayo Clinic - RochesterRochester, United States
- UC San Francisco Medical CenterSan Francisco, United States
- Baystate Medical CenterSpringfield, United States
- Stanford HealthcareStanford, United States
- Montefiore Medical CenterThe Bronx, United States
- Wake Forest Univ School of MedicineWinston-Salem, United States
About the trial
What the trial wants to find out
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
The 4 groups in the trial
- TIN816 Dose ATreatment being tested
Administered as a one time intravenous dose
Treatment: TIN816 70 mg lyophilisate powder
- TIN816 Dose BTreatment being tested
Administered as a one time intravenous dose
Treatment: TIN816 70 mg lyophilisate powder
- TIN816 Dose CTreatment being tested
Administered as a one time intravenous dose
Treatment: TIN816 70 mg lyophilisate powder
- PlaceboPlacebo, for comparison
0.9% sterile saline administered as a one time intravenous dose
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
- Record updated
- 29 July 2026